PI3K activation leads to the inhibition of NF-κB and activation of C/EBPβ, thereby initiating an immunosuppressive transcriptional program.110 Knockout of PI3K was found to reduce the accumulation of PMN-MDSC in tumour-bearing mice, breaking immune tolerance to cancer.111 Inhibition of both isoforms of this kinase delayed tumour growth and prolonged survival in tumour models of head and neck cancer, when used in combination with a PD-L1 blocking antibody, indicating a beneficial effect of MDSC inhibition in combination with immune-checkpoint inhibition.112. The gene discussed is CEBPB; the disease is neoplasm.